A Different Fate: Heather Morgan’s Fight Against Ovarian Cancer Due to Cross-Border Healthcare Disparities

I might have avoided ovarian cancer – Heather Morgan’s journey with cancer began in 2014 when she was diagnosed with breast cancer. Had she been in England instead of Wales at the time, she believes there’s a strong possibility she might have prevented the development of ovarian cancer altogether. The difference lies in her postcode—a small village eight miles west of the English border in Monmouthshire, where genetic testing for high-risk cancer mutations was not routinely offered to patients like her. This oversight, she argues, has had life-changing consequences.

For women in England with triple negative breast cancer under the age of 50, genetic screening was an automatic priority. In Wales, however, the same protocol was not in place. Heather, then 46, was not invited for the test despite her young age and the aggressive nature of her cancer. The test, which identifies BRCA gene mutations, could have revealed her heightened risk for ovarian cancer. “I am mad annoyed,” Heather said, reflecting on the missed opportunity. “It’s changed everything.”

“I am mad annoyed. It’s changed everything,” Heather said, explaining that her 10-year survival chances are only 35%.

It wasn’t until 2021 that a noticeable lump in her abdomen led to further investigation, resulting in an ovarian cancer diagnosis. At that point, she learned she carried the BRCA1 gene mutation, which significantly raises the likelihood of developing both breast and ovarian cancer. “Had I been tested in 2014, we would have immediately known I was at high risk for ovarian cancer,” she said. “I would have had my ovaries removed right away. It would have been a no-brainer.”

Heather’s experience highlights the “postcode lottery” in healthcare. She retains the letter from the Welsh genetic testing service that explained her ineligibility. It cited the Welsh government’s commitment to meeting NICE (National Institute for Health and Care Excellence) guidelines within the financial year, but also noted that testing capacity was still being expanded. By 2021, the rules had aligned with England’s, yet Heather had already completed her treatment and missed the opportunity for early intervention.

The Welsh government has since taken steps to address such disparities. A minister for preventative and public health has been appointed to focus on improving early detection strategies. However, for Heather, the delay was costly. “If I’m going to the supermarket and I’ve gone a bit over budget, I’ll think, why save money? What’s the point, you’ll be dead next week, just buy it,” she said. “Something came through the post about retirement homes—am I going to live that long? Should I be worrying about that? No.”

BRCA Gene Mutations and Their Implications

BRCA1 and BRCA2 gene mutations are known to significantly increase the risk of certain cancers. For women in the UK, the average lifetime risk of breast cancer is 12.5%, and ovarian cancer is 2%. However, for those with BRCA1 mutations, these risks jump to 72% for breast cancer and 44% for ovarian. BRCA2 mutations carry slightly lower risks—69% for breast and 17% for ovarian—but both genes elevate the chance of developing cancer at a younger age.

Heather’s case underscores the importance of genetic testing. Early detection can mean the difference between a preventive procedure and a life-threatening diagnosis. The helpline she now supports, the National Hereditary Breast Cancer Helpline, has become a vital resource for patients navigating these complexities. Founded by Wendy Watson, the helpline recently established its first information center in Flint, north Wales, and is expanding to offer support for cancers linked to BRCA mutations across the UK.

“We do have postcode lottery healthcare,” said Wendy Watson, the helpline’s founder. “We shouldn’t have—NICE guidelines should sort that out, but at least we’re here to provide people with access to the information.”

Heather’s family has witnessed similar discrepancies within England itself. Her two adult daughters, though both at risk, received conflicting advice. One daughter in the north-east of England was invited for genetic testing, while her eldest daughter in the north-west was not. These inconsistencies further emphasize the challenges patients face when dealing with inherited cancer risks.

Despite the setbacks, Heather remains determined to raise awareness about the importance of early screening. “It’s not just about me,” she said. “It’s about other women who might have a similar story but don’t know they’re at risk.” Her advocacy aligns with the helpline’s mission to ensure individuals are informed about their options and the rules governing genetic testing. The service now provides guidance on MRIs and mammograms for BRCA mutation carriers, including annual scans starting at age 30-49 and continuing into the 40s.

Disparities Across the UK

While the Welsh government has made progress in harmonizing its approach with England’s, the issue of uneven healthcare access persists. Heather’s story is not unique, and others in Wales and England face similar challenges. For instance, Louise Owen, a 36-year-old woman with a BRCA2 mutation, has relied on the helpline for support. Like Heather, she has known for over a decade that she is at higher risk but has had to navigate varying guidelines and waiting times.

Such disparities have prompted calls for more consistent protocols across the UK. Patients often find themselves in a position where their survival chances depend on their location. “There’s a common theme of conflicting advice and discrepancies,” said Louise, emphasizing the helpline’s role in bridging gaps in information and care. While the National Health Service aims to standardize practices, the reality remains that access to services can vary widely, even within the same country.

Heather’s story is a reminder of how critical early intervention is in cancer management. By 2014, she could have had her ovaries removed preemptively, potentially saving her life. Today, her advocacy continues to drive awareness, urging others to take action before it’s too late. “If they’d have said to have a double mastectomy at that point, I would have,” she said, underscoring the urgency of identifying genetic risks as early as possible.